

26 Jun 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer's disappointment for Roche; Japan speed bump for Shionogi's oral COVID antiviral; pharma's view of psychedelics; and a roundup of key BIO sessions.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 24 June 2022, including: [Genmab A/S](#) confident in CD20xCD3 battle; Alzheimer's disappointment for [Roche Holding AG](#); Japan speed bump for [Shionogi & Co. Ltd.](#)'s oral COVID antiviral; pharma's view of psychedelics; and a roundup of key BIO sessions.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Genmab Confident It Has Edge Over Roche In Bispecific Battle](#)" - Scrip, 17 Jun, 2022.)

(Also see "[Failure Of Roche's Nine-Year Alzheimer's Prevention Study Disappointing, But No Surprise](#)" - Scrip, 16 Jun, 2022.)

(Also see "[Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug](#)" - Scrip, 22 Jun, 2022.)

(Also see "[More De-Risking Required Before Pharma Dives Into Psychedelics](#)" - Scrip, 20 Jun, 2022.)

(Also see "[BIO 2022 Notebook: Future Directions For R&D](#)" - Scrip, 16 Jun, 2022.)

[Click here to explore this interactive content online](#) 